2025 North America Ai-Based Clinical Trials Revenue Opportunities Report
Description
The 2025 North America Ai-Based Clinical Trials Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the AI-based Clinical Trials by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in AI-based clinical trials in North America include IQVIA, Johnson & Johnson MedTech, Tempus, and Saama. IQVIA is the largest Contract Research Organization (CRO) globally, leveraging advanced analytics and AI-driven technology solutions to enhance clinical research and trial services with over $15 billion revenue reported in 2024. Johnson & Johnson MedTech integrates AI in surgical robotics and clinical genomics, partnering with NVIDIA to scale real-time AI analytics in clinical settings. Tempus specializes in precision medicine using AI platforms that integrate genomic and clinical data to improve patient matching and drug discovery, especially in oncology. Saama, awarded the Best AI-Based Solution for Life Sciences in 2024, focuses on real-time data integration and analytics to optimize clinical trial success rates and timelines.
These companies use AI to tackle inefficiencies such as patient recruitment, data analysis, and trial design. IQVIA continually innovates through acquisitions and enhanced AI laboratories to provide comprehensive clinical trial solutions. Johnson & Johnson's AI-powered platforms support digital surgery and biomarker discovery. Tempus’s machine learning models predict therapy responses and facilitate trial matching through natural language processing of unstructured clinical notes. Saama offers integrated AI platforms improving decision-making and deep analytics in trial processes. Collectively, their AI capabilities accelerate trial timelines, reduce costs, and improve patient diversity and outcome predictions in North American clinical trials.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the AI-based Clinical Trials by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in AI-based clinical trials in North America include IQVIA, Johnson & Johnson MedTech, Tempus, and Saama. IQVIA is the largest Contract Research Organization (CRO) globally, leveraging advanced analytics and AI-driven technology solutions to enhance clinical research and trial services with over $15 billion revenue reported in 2024. Johnson & Johnson MedTech integrates AI in surgical robotics and clinical genomics, partnering with NVIDIA to scale real-time AI analytics in clinical settings. Tempus specializes in precision medicine using AI platforms that integrate genomic and clinical data to improve patient matching and drug discovery, especially in oncology. Saama, awarded the Best AI-Based Solution for Life Sciences in 2024, focuses on real-time data integration and analytics to optimize clinical trial success rates and timelines.
These companies use AI to tackle inefficiencies such as patient recruitment, data analysis, and trial design. IQVIA continually innovates through acquisitions and enhanced AI laboratories to provide comprehensive clinical trial solutions. Johnson & Johnson's AI-powered platforms support digital surgery and biomarker discovery. Tempus’s machine learning models predict therapy responses and facilitate trial matching through natural language processing of unstructured clinical notes. Saama offers integrated AI platforms improving decision-making and deep analytics in trial processes. Collectively, their AI capabilities accelerate trial timelines, reduce costs, and improve patient diversity and outcome predictions in North American clinical trials.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
